Compare Davita Inc (DVA) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while Invesco S&P 500 Low Volatility ETF trades at $75.93. The key difference: Davita Inc is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals.
| DVA | SPLV | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | — |
52-Week High | $235.71 | $77.45 |
52-Week Low | $103.87 | $70.30 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
SPLV trades at $76.41, up 0.75% with a bullish technical signal from moving averages. The ETF provides exposure to 100 S&P 500 stocks with the lowest volatility, maintaining strong defensive characteristics with no calendar-year losses exceeding 5% historically. Recent market volatility has increased investor interest in low-volatility strategies as tech valuations remain stretched.
The outlook remains positive given ongoing market uncertainty and inflation concerns. SPLV's defensive positioning offers portfolio stability, though concentrated sector exposure and quarterly rebalancing present implementation risks. The ETF's $6.93 billion in assets demonstrates institutional confidence in its low-volatility approach.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
